Close Menu

NEW YORK (GenomeWeb) — Adaptive Biotechnologies said today that it has signed an agreement with Genentech to use its TruTCR T-cell receptor (TCR) screening platform to help the drug company develop personalized cancer therapies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.